Prevalence of peripheral neuropathy in Egyptian hepatitis C virus patients: Correlation to some clinical and laboratory parameters

Khalek, Manal Aly Abdel; El-Barbary, Amal Mohamad; El-Kalla, Ferial; Essa, Salwa A.

doi:10.1016/j.ejr.2012.04.001

Cited by 7 publications

(11 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Neuropathic pain was present in 9.1% of our study population, assessed by the NPDQ tool. Our proportion is lower than the 43.7% reported in a study in Egypt and 42% reported in Italy [ 13 , 32 ]. This difference is most likely due to the difference in tools used for neuropathic pain assessment and the heterogeneity in populations studied.…”

Section: Discussioncontrasting

confidence: 86%

“…Our prevalence is similar to the 45% clinical neuropathy reported by Manal et al . in Egypt [ 13 ], and 43.5% by Yoon et al . in Germany [ 23 ].…”

Section: Discussionmentioning

confidence: 99%

“…(100% sensory) in Egypt and Biasiotta et al . (96% sensory) [ 13 , 24 , 32 ]. This predominance of sensory peripheral neuropathy is in line with Sterling and Bralow, who demonstrated that sensory deficiencies are more common than motor loss, and that sensory symptoms may persist for months to years before any motor deficit becomes clinically evident [ 33 ].…”

Section: Discussionmentioning

confidence: 99%

“…The most studied HCV associated neurological conditions include: peripheral neuropathy, cognitive impairment and cerebrovascular accidents [ 10 , 12 , 13 ]. Peripheral neuropathy is the commonest and best established HCV related neurological complication, affecting more than half of infected patients in some populations [ 12 , 13 ]. The pathogenesis of these manifestations remain largely speculative.…”

Section: Introductionmentioning

confidence: 99%

“…Egypt is the only African country with published information on these manifestations. Manal et al reported the prevalence of peripheral neuropathy as 67.5% in a group of Egyptian HCV infected treatment naïve patients [ 13 ]. The most reported factors associated with neurological manifestations in HCV infection are cryoglobulinaemia, advanced age and duration of illness [ 16 – 18 ].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Neurological manifestations in chronic hepatitis C patients receiving care in a reference hospital in sub-Saharan Africa: A cross-sectional study

et al. 2018

View full text Add to dashboard Cite

BackgroundChronic hepatitis C infection is a major public health concern, with a high burden in Sub-Saharan Africa. There is growing evidence that chronic hepatitis C virus (HCV) infection causes neurological complications. This study aimed at assessing the prevalence and factors associated with neurological manifestations in chronic hepatitis C patients.MethodsThrough a cross-sectional design, a semi-structured questionnaire was used to collect data from consecutive chronic HCV infected patients attending the outpatient gastroenterology unit of the Douala General Hospital (DGH). Data collection was by interview, patient record review (including HCV RNA quantification, HCV genotyping and the assessment of liver fibrosis and necroinflammatory activity), clinical examination complemented by 3 tools; Neuropathic pain diagnostic questionnaire, Brief peripheral neuropathy screen and mini mental state examination score. Data were analysed using Statistical package for social sciences version 20 for windows.ResultsOf the 121 chronic hepatitis C patients (51.2% males) recruited, 54.5% (95% Confidence interval: 46.3%, 62.8%) had at least one neurological manifestation, with peripheral nervous system manifestations being more common (50.4%). Age ≥ 55 years (Adjusted Odds Ratio: 4.82, 95%CI: 1.02–18.81, p = 0.02), longer duration of illness (AOR: 1.012, 95%CI: 1.00–1.02, p = 0.01) and high viral load (AOR: 3.40, 95% CI: 1.20–9.64, p = 0.02) were significantly associated with neurological manifestations. Peripheral neuropathy was the most common neurological manifestation (49.6%), presenting mainly as sensory neuropathy (47.9%). Age ≥ 55 years (AOR: 6.25, 95%CI: 1.33–29.08, p = 0.02) and longer duration of illness (AOR: 1.01, 1.00–1.02, p = 0.01) were significantly associated with peripheral neuropathy.ConclusionOver half of the patients with chronic hepatitis C attending the DGH have a neurological manifestation, mainly presenting as sensory peripheral neuropathy. Routine screening of chronic hepatitis C patients for peripheral neuropathy is therefore necessary, with prime focus on those with older age and longer duration of illness.

show abstract

Section: Discussioncontrasting

confidence: 86%

“…Our prevalence is similar to the 45% clinical neuropathy reported by Manal et al . in Egypt [ 13 ], and 43.5% by Yoon et al . in Germany [ 23 ].…”

Section: Discussionmentioning

confidence: 99%